Compare TYGO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYGO | ADCT |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.0M | 136.1M |
| IPO Year | 2021 | 2019 |
| Metric | TYGO | ADCT |
|---|---|---|
| Price | $1.17 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 1.7M | 796.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | 30.86 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $103,536,000.00 | $81,357,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $21.68 | $66.49 |
| P/E Ratio | $123.00 | ★ N/A |
| Revenue Growth | ★ 91.68 | 14.85 |
| 52 Week Low | $0.93 | $0.78 |
| 52 Week High | $5.33 | $4.98 |
| Indicator | TYGO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 40.12 |
| Support Level | N/A | $1.03 |
| Resistance Level | $1.73 | $1.17 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 20.26 | 39.22 |
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).